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cytokinemia and pan-cytopenias, including T and B lymphopenias. The developing immune cells in the bone
marrow are known to express a variety of cytokine and inflammatory receptors yet the effects of signaling
through these receptors on hematopoiesis is incomplete. Since many infectious and autoimmune syndromes
result in sustained TLR9 stimulation, understanding the effects of TLR9 driven inflammation on
hematopoiesis is important for both questions of pathogenesis as well as possible therapeutic interventions
that might help to restore homeostasis. Utilizing in vitro and in vivo techniques, we demonstrate that B
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different effects inhibiting development at multiple stages across B cell development. We show that TLR9
signaling directly decreases in vitro B cell yields from CLPs, Pro and Pre B cells yet increases T cell yields.
While TLR9 can inhibit B cell growth in vitro, using mixed bone marrow chimeras, we show in vivo that this
TLR9 intrinsic effect is masked, likely due to other TLR9 induced inflammatory factors that also mediate
decreases in B lymphopoiesis. This led us to demonstrate that IFN-γ also directly inhibits B cell differentiation
in vitro as well as when induced by TLR9 in vivo. Microarray and RT-PCR analysis of Ly-6D- CLPs points to
HOXa9 as an early B-cell directing transcription factor that is altered by TLR9 induced inflammation, as it
and many of its known targets are decreased in Ly-6D- CLPs. Additionally EBF-1, another factor essential for
initiation of the B cell program was transcriptionally decreased in Ly-6D- and Ly-6D+ CLPs. Our work
demonstrates both cellular and molecular targets that lead to altered B-lymphopoiesis in sustained TLR9
driven inflammation that may be relevant in a number of infectious and autoimmune/inflammatory settings.
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ABSTRACT 
 
TOLL-LIKE RECEPTOR 9 AND INTFERON-GAMMA RECEPTOR SIGNALING 
SUPPRESS THE B CELL FATE OF UNCOMMITTED PROGENITORS IN MICE 
Sheena Baratono 
Edward M. Behrens 
 
Hyperinflammatory syndromes come in a variety of flavors with different 
immunogens and cytokines leading to variations in organ pathology. This inflammation 
can be driven by viral, autoimmune, or neoplastic conditions leading to profound and 
widespread organ pathology including hepatitis, fever, splenomegaly, cytokinemia and 
pan-cytopenias, including T and B lymphopenias. The developing immune cells in the 
bone marrow are known to express a variety of cytokine and inflammatory receptors yet 
the effects of signaling through these receptors on hematopoiesis is incomplete. Since 
many infectious and autoimmune syndromes result in sustained TLR9 stimulation, 
understanding the effects of TLR9 driven inflammation on hematopoiesis is important for 
both questions of pathogenesis as well as possible therapeutic interventions that might 
help to restore homeostasis. Utilizing in vitro and in vivo techniques, we demonstrate that 
B lymphopoiesis is inhibited during TLR9 driven inflammation from the Ly-6D+ CLP 
stage onwards with different effects inhibiting development at multiple stages across B 
cell development. We show that TLR9 signaling directly decreases in vitro B cell yields 
from CLPs, Pro and Pre B cells yet increases T cell yields. While TLR9 can inhibit B cell 
growth in vitro, using mixed bone marrow chimeras, we show in vivo that this TLR9 
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intrinsic effect is masked, likely due to other TLR9 induced inflammatory factors that 
also mediate decreases in B lymphopoiesis. This led us to demonstrate that IFN-γ also 
directly inhibits B cell differentiation in vitro as well as when induced by TLR9 in vivo. 
Microarray and RT-PCR analysis of Ly-6D- CLPs points to HOXa9 as an early B-cell 
directing transcription factor that is altered by TLR9 induced inflammation, as it and 
many of its known targets are decreased in Ly-6D- CLPs. Additionally EBF-1, another 
factor essential for initiation of the B cell program was transcriptionally decreased in Ly-
6D- and Ly-6D+ CLPs. Our work demonstrates both cellular and molecular targets that 
lead to altered B-lymphopoiesis in sustained TLR9 driven inflammation that may be 
relevant in a number of infectious and autoimmune/inflammatory settings.  
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Chapter 1 
Introduction 
 
Systemic hyperinflammation comes in a variety of flavors with different 
immunogens and cytokines leading to variations in organ pathology. This inflammation 
can be initiated by infectious, genetic, traumatic, autoimmune or neoplastic conditions, 
all leading to profound and widespread organ damage. This pathology includes hepatitis, 
fever, splenomegaly, cytokinemia and pan-cytopenias, specifically T and B lymphopenias 
and in severe cases, hemodynamic insufficiency and death. (Behrens et al., 2011; Canna 
et al., 2013; Hinze et al., 2010; Zhang et al., 2014a) The widespread inflammation affects 
a variety of organ systems including the bone marrow, which is the site of hematopoiesis. 
While bone marrow hematopoietic progenitors express several cytokine and 
inflammatory receptors, our knowledge regarding the effects of signaling through these 
receptors on hematopoiesis is incomplete. Phenotypic variations in the inflammation 
depend on the inciting pathogenic factors and the cytokine networks they induce. One 
common thread across various causes of inflammation is that lymphopoiesis is 
diminished in the bone marrow, specifically leading to drastic reductions in B and T 
lymphopoiesis. 
 
Diseases of hyperinflammation 
Bacterial mediated sepsis induces profound inflammation through stimulation of 
Toll-Like Receptors (TLR), primarily TLR4, which recognizes the microbial 
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lipopolysaccharide moiety. Stimulation of TLR4 on myeloid cells releases high levels of 
tumor necrosis factor α (TNFα) and interleukin (IL) -1 leading to widespread 
inflammation and hemodynamic instability.(Beutler and Poltorak, 2001) In mice, chronic 
low dose lipopolysaccharide stimulation through TLR4 and the resulting cytokine release 
inhibit hematopoietic stem cell quiescence inducing them to differentiate. (Esplin et al., 
2011) Serial bone marrow transplants of stem cells from inflamed mice show that the 
inflammation skews stem cells away from the lymphoid lineages. (Esplin et al., 2011; 
Nagai et al., 2006) In this model, myelopoiesis in the bone marrow was also decreased 
while B cell numbers in the spleen were increased suggesting that inflammation alters 
multiple hematopoietic lineages. 
Superantigens produce sudden and profound inflammation by non-specific 
activation of T cells caused by cross-linking T cell receptors or their ligands, the major 
histocompatibility complex. This non-discriminate activation leads to T cell release of 
interferon-γ (IFN-γ), which activates macrophages to produce IL-1, IL-6 and TNFα.  
(Edwards et al., 1996) These cytokines lead to fever, splenomegaly and shock or 
hemodynamic instability. In studies using human and canine cells, antibodies that cross-
link the major histocompatibility complex molecule HLA-DR mimicking superantigens 
severely diminish hematopoiesis, in part due to increased apoptosis and decreased levels 
of stem cell factor. (Hong et al., 1995; Lee et al., 1997; Yamaguchi et al., 1999) In these 
mice lymphoid progenitors were decreased in the bone marrow but increased in the 
blood, while myeloid progenitors were increased in the bone marrow. This suggests that 
inflammation may drive hematopoiesis towards certain lineages at the expense of others. 
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Patients with primary Hemophagocytic Lymphohistiocytosis (HLH) have defects 
in the machinery associated with cytotoxicity of functions of T and natural killer (NK) 
cells. They develop profound cytokine storm induced inflammation upon infection with 
various pathologic agents. (Zhang et al., 2014a) By being unable to clear the infection, 
the immune system is constantly bombarded with increasing levels of pathogenic stimuli 
leading to release of high levels of IFN-γ, TNFα and other inflammatory cytokines. 
Macrophage activation syndrome is a form of HLH that associates with rheumatologic 
disorders including systemic lupus erythematosus and juvenile idiopathic arthritis. 
(Zhang et al., 2014a) While it is still unclear why some lupus and arthritis patients 
develop macrophage activation syndrome, lupus in particular is associated with the 
immune system responding to apoptotic debris in a pro-inflammatory manner. Apoptotic 
debris engulfed by phagocytic cells can stimulate TLR9 and in abnormal cases, drive an 
adaptive immune response. (Biermann et al., 2014; Munoz et al., 2010; Zhang et al., 
2010) Plasmacytoid and traditional dendritic cells respond to the apoptotic debris 
releasing both type 1 and type 2 interferons which drive further inflammation. (Biermann 
et al., 2014) Many HLH patients have decreased peripheral B and T cell counts as well as 
poor rates of bone marrow engraftment upon transplantation, suggesting that the 
hematopoietic compartment is altered during inflammation. (Hinze et al., 2010; Sumegi 
et al., 2011) 
A variety of viral infections are linked to induction of aplastic anemia with 
decreases in erythropoiesis, leukopoiesis, and thrombopoiesis. The viruses associated 
with aplastic anemia in humans are heterogeneous and include parvovirus B19, Epstein-
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Barr virus, cytomegalovirus, human immunodeficiency virus, dengue, measles virus and 
hepatitis C. (Nakao et al., 1989; Ozawa et al., 1987) While the patterns of infection 
among these viruses vary, they all induce high levels of IFN-γ, an inverted cluster of 
differentiation (CD) 4:8 ratio and increased CD8 cytotoxicity. (Nakao et al., 1989; Ozawa 
et al., 1987) Some of these viruses directly infect bone marrow progenitor cells leading to 
disruption of normal hematopoiesis.  Others alter the ability of bone marrow stromal cells 
to support normal hematopoietic development in response to various inflammatory 
cytokines and stimuli. (Manchester et al., 2002; Rosenfeld and Young, 1991; Simmons et 
al., 1990; Young et al., 1987) 
Multicentric Castelman’s disease is a lymphoproliferative, cytokine storm 
disorder sometimes associated with human herpes virus-8.  Idiopathic, or non-human 
herpes virus-8 associated, multicentric Castelman’s disease is a diagnosis of exclusion 
when other autoimmune, infectious, and neoplastic disorders are ruled out. (Fajgenbaum 
et al., 2014) In this disorder, polyclonal lymphocytes become highly activated and 
produce high quantities of various cytokines. The most common dominating cytokines 
are IL-6 and type 1 interferons. (Muskardin et al., 2012) The cytokine storm and side 
effects of the various chemotherapy and immuno-regulatory therapies severely alter the 
hematopoietic compartment leaving patients immuno-suppressed post resolution of the 
inflammatory periods. 
A variety of infectious, autoimmune, and neoplastic conditions can induce 
hyperinflammation. Patients with these inflammatory disorders display widespread organ 
damage with variations depending on the inciting factor and the dominating cytokines 
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within the inflammatory cascade. Many of them also have alterations in hematopoiesis 
and develop prolonged lymphopenias leaving the patients immuno-suppressed even after 
recovery from the initiating incident. How inflammation alters hematopoiesis and the 
long-term ramifications of these changes are still unclear.  
 
Normal murine B and T lymphopoiesis 
The progression from undifferentiated hematopoietic stem cell to mature 
lymphocyte has been well characterized in murine models. During non-inflammatory 
conditions, hematopoietic stem cells differentiate towards the lymphoid lineage losing 
long-term self-renewal capabilities. These cells are termed multipotent progenitors. 
(Beaudin et al., 2014; Luc et al., 2008) A subset of these multipotent progenitors 
upregulate FMS-like tyrosine kinase 3 (Flt3) and are termed lymphoid primed 
multipotent progenitors (LMPP). These LMPPS have no erythroid and megakaryocyte 
potentials and limited myeloid potential.(Beaudin et al., 2014) Some of these LMPPs 
migrate further towards the lymphoid lineages, upregulating IL-7Rα and are termed 
common lymphoid progenitors (CLPs). These CLPs are defined as being Lineage-
Sca1intcKitintIL-7Rα+Flt3+. (Harman et al., 2008) They express high levels of the 
transcription factors homeobox A9 (Hoxa9) and transcription factor 3 (E2A), which 
contribute to upregulation of the cell surface receptors Flt3 and IL-7 receptor α (IL-7Rα) 
whose ligands further support lymphoid development.(Bain et al., 1994; Gwin et al., 
2013a; Rolink et al., 1999; Seet et al., 2004) CLPs however are a heterogeneous 
population; CLPs expressing Ly-6D+, are exclusively committed to the B cell lineage in 
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vivo, while the Ly-6D- CLPs can give rise to B, T, NK, or dendritic cells. (Allman et al., 
1999; Inlay et al., 2009; Mansson et al., 2010) These Ly-6D+ CLPs retain the ability to 
generate T cells in vitro on OP9-dl1 cultures but do not generate T cells in vivo by 
intrathymic injection. (Inlay et al., 2009) The Ly-6D+ CLPs begin to express high levels 
of early B cell factor 1 (EBF-1), which specifies the B cell fate and turns on paired box 5 
(PAX5) and other B cell factors that are important for initiating and maintaining the B 
cell program. (Lin and Grosschedl, 1995; Pongubala et al., 2008; Rolink et al., 1999; Seet 
et al., 2004; Tsapogas et al., 2011) As these B cell promoting transcription factors are 
turned on, the progenitors also turn on recombination activating gene (RAG) and 
rearrange the heavy chain of the B cell receptor (BCR). (Allman et al., 1999) Pro B cells 
are committed to the B cell lineage and express CD19, CD93, protein tyrosine 
phosphatase receptor type C (B220), and CD43. (Hardy et al., 1991) Upon successful 
rearrangement of the heavy chain, these cells downregulate CD43 and undergo several 
rounds of proliferation as Pre B cells. After successful rearrangement of the light chain, 
the progenitors express surface IgM and are considered Immature B cells. (Hardy et al., 
1991) These cells can then leave the bone marrow and finish development in the spleen. 
These peripheral developing B cells are termed Transitional B cells and are differentiated 
by their expression of surface IgM and CD23. Stimulation of Transitional 1 or 2 B cells 
through their B cell receptor leads to apoptosis while stimulation of the more mature 
Transitional 3 cells leads to proliferation and further maturation, suggesting that 
downstream signaling fates are changed as cells mature. (Carsetti et al., 1995) 
Unlike B cell development, potential T ell progenitors must leave the bone 
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marrow and travel through the circulation to the thymus where they receive instructing 
signals that drive the T cell fate. These thymic settling progenitors can arise from the Ly-
6D- CLPs or straight from the LMPPs. (Chi et al., 2009) Of these early progenitors, those 
that express the chemokine (C-C motif) receptors (CCR) CCR7 and CCR9 are able to 
successfully home to the thymus where high levels of notch ligands on the thymic stroma 
initiate the T cell transcriptional program while also repressing factors important for B 
cell development. (Pui et al., 1999; Zhang et al., 2014b; Zlotoff et al., 2010) These 
thymic settling progenitors are positive for stem cell growth factor receptor (cKit) but 
negative for CD25, CD4 and CD8a and are termed early thymic progenitors (ETP). 
(Bhandoola et al., 2007) ETPs retain NK and dendritic cell (DC) potential. The ETPs 
then begin to express CD25 and are termed double negative (DN) 2 cells. As cKit 
expression decreases, the cells lose DC potential. (Germain, 2002) The CD25+ cKit- cells 
are the DN3 thymocytes, which undergo selection for the T cell receptor. These cells can 
mature into two broadly different T cell lineages, the gamma-delta T cells and alpha-beta 
T cells, named by their T cell receptor (TCR) expression. DN3 cells that successfully 
rearrange the gamma-delta TCR go on to become mature gamma-delta T cells. 
(Rothenberg, 2000) DN3 cells that successfully rearrange the beta chain progress to the 
DN4 stage where they downregulate CD25 and prepare to upregulate CD4 and CD8a. 
(Bhandoola et al., 2007; Germain, 2002) The CD4 and CD8a double positive cells (DP) 
then undergo rearrangement of the alpha chain and express the full alpha-beta TCR on 
their surface. Cells successfully rearranging TCRs enter positive selection where the 
affinity of the newly arranged TCR for self-peptide-major histocompatibility complexes 
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is assessed. These DP cells are highly susceptible to apoptosis as they become refractive 
to IL-7, a pro-survival cytokine, due in part to decreased IL-7 receptor expression. 
(Ribeiro et al., 2013) DPs are therefore sensitive to glucocorticoids and other external 
stimuli that induce apoptosis. More than 90% of these DP thymocytes undergo death by 
neglect due to non-appropriate TCR rearrangements. (Brewer et al., 2002; Lu et al., 2000) 
DP cells that successfully undergo positive selection progress to the CD4 and CD8a 
single positive T cell lineages where they undergo negative selection for auto-reactive 
TCRs and exit the thymus. 
 
B and T lymphopoiesis during inflammation 
Depending on the inflammatory model and which cytokines are produced, 
different components of hematopoiesis are impacted. In a model where mice are 
immunized with nitro phenol-chicken gamma globulin in incomplete Freund’s adjuvant, 
both bone marrow B lymphopoiesis and myelopoiesis are altered. The B cell defect is due 
in part by migration of some B cell precursors to the spleen. (Borrow et al., 2005; Ueda et 
al., 2005; Ueda et al., 2004) The mobilization was revealed to be due to TNFα mediated 
decreases in C-X-C motif chemokine ligand (CXCL) 12, which is important for 
maintaining the B cell niche in the bone marrow. (Ueda et al., 2005; Ueda et al., 2004) 
While CXCL12 levels recover within 8 days post-immunization, it is unclear how 
repeated exposure to adjuvant-induced inflammation would alter TNFα and CXCL12 
levels. In this same model, IL-1 or treatment with pertussis toxin, a broad chemokine 
receptor blocker, increases granulopoiesis, leading to a net shift in production of 
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granulocytes. (Ueda et al., 2005; Ueda et al., 2004) This may be due to the decrease in B 
lymphopoiesis opening up space for increased granulopoiesis in the marrow or to 
independent actions of differing cytokines. In T cell development, TNFα and IL-1 have 
been shown to increase expression of CD25 in fetal thymic organ cultures. Blockade of 
TNFα and IL-1 leads to decreased CD25 expression and impaired development of DP 
thymocytes. (Zuniga-Pflucker et al., 1995) These data suggest that TNFα and IL-1 have 
differing affects on B and T lymphopoiesis.  
Studies looking at cultures of multipotent progenitors in vitro found that addition 
of recombinant IL-6 to single cell cultures inhibited B cell potential but increased 
myeloid potential. (Jenkins et al., 2007; Maeda et al., 2010) However, when single RAG+ 
early lymphoid progenitors were plated, addition of IL-6 increased B cell yields. (Maeda 
et al., 2005) This suggests that IL-6 acts differentially on multipotent progenitors to 
inhibit lymphoid fates, but once the cell is already committed to the lymphoid lineages, it 
may enhance differentiation or proliferation. In an in vivo mouse model of lupus with 
high levels of serum IL-6, mice had significantly decreased bone marrow B cell and CLP 
numbers, which were restored when the mice were crossed to an IL-6 null background. 
(Maeda et al., 2009) In a different mouse model with increased IL-6 receptor signaling, 
thymocytes expressed higher levels of IL-6 transcripts and proteins than WT controls. 
(Jenkins et al., 2007) The thymocytes also expressed higher levels of IL-6Rα suggesting 
that they are both making and responding to IL-6 in an enhanced manner. Surprisingly, 
these mice had increased thymic cellularity yet decreased percentages of DPs suggesting 
that different thymocyte subsets also react differentially to IL-6. (Jenkins et al., 2007) 
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These studies suggest that IL-6, like BCR and TCR signaling, has varying effects 
depending on the stage of development of the precursor. 
Type 1 interferons significantly alter hematopoiesis in a lymphocytic 
choriomeningitis virus (LCMV)-WE model of infection. Three days after infection with 
LCMV-WE, wildtype (WT) and IFN-γR knockout (IFN-γRKO) mice had <1% normal 
bone marrow cellularity, with impaired abilities to generate granulocytes, erythrocytes, 
and megakaryocytes. IFNα-RKO mice, however, mimic uninfected controls with normal 
rates of hematopoiesis. (Binder et al., 1997) In another study looking at exogenous 
treatment of IFNα2/α1 in neonatal mice, B lymphopoiesis was severely impaired and Pre 
B cells exhibited decreased proliferation in response to IL-7. (Lin et al., 1998) 
Thymopoiesis was also affected in this model, with the largest thymocyte reductions 
occurring in the DP compartment. (Lin et al., 1998) However, it is unclear if these 
decreases are a direct effect of the interferons on the precursor cells. Administration of 
type 1 interferons to fetal thymic organ cultures lead to decreased thymic cellularity with 
the largest decrease occurring at the DN3 stage, suggesting a block during beta chain 
rearrangement. (Baron et al., 2008) However, administration of recombinant type 1 
interferons to OP9-dl1 fetal derived hematopoietic stem cell co-cultures lead to a block in 
T cell development at the DN1 stages with increased annexin-V staining cells. Together, 
these data suggest that high levels of type 1 interferons impair lymphopoiesis at multiple 
stages of T and B cell development in vivo and in vitro. 
IFN-γ also inhibits lymphopoiesis in in vivo and in vitro models. B lymphopoiesis 
was diminished in T cell protein tyrosine phosphatase null mice due to aberrant stromal 
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cell secretion of IFN-γ. The Pre B cells from these mice also demonstrated impaired 
proliferation in response to IL-7, suggesting IFN-γ may be inhibiting responses to pro-
survival cytokines. (Bourdeau et al., 2007) However, Pre B cells kept in culture with IL-7 
and IFN-γ did not show increased rates of apoptosis within the first 48 hours in culture. 
(Bourdeau et al., 2007) Transgenic mice expressing IFN-γ under the Ig-lambda enhancer 
had varying phenotypes, with some mice becoming moribund while others remained 
stable. These mice have severe defects in B lymphopoiesis and severe B cell loss in the 
periphery. (Young et al., 1997) They also have increased expression of IFN-γ in the 
thymus and increased thymic cellularity with higher numbers of both CD4 and CD8 
single positive thymocytes but significantly fewer numbers of DPs. (Young et al., 1997) 
The increase in single positive thymocytes may be due to proliferation of precursors in 
response to IFN-γ or increased homing of mature T cells via the circulation. 
Histologically, thymii from healthy transgenic mice were normal while those from 
moribund transgenic mice showed severe atrophy, possibly due in part to stress and 
glucocorticoid release.  (Young et al., 1997) Together these data suggest that IFN-γ 
inhibits IL-7 responsiveness and B and T lymphopoiesis, but it is unclear whether it is 
acting directly on the precursors. 
Another report looking at the effects of microbial products on B lymphopoiesis 
found that stimulation through TLR9 with CpG or acute herpes simplex virus infection 
leads to lower Pre B cells but increased bone marrow plasmacytoid dendritic cell 
numbers. (Welner et al., 2008) While the reduction in B cells was dependent on TLR9 
signaling, TNFα also played a partial role in mediating the decrease in B cell precursors 
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in the bone marrow. However it but did not contribute to the increase in dendritic cells, 
suggesting that they are not entirely reciprocal processes. In addition to decreased B 
lymphopoiesis in vivo, CpG or herpes simplex virus administration appeared to alter the 
lineage potential of CLPs in these models when they were placed in in vitro cultures. 
(Esplin et al., 2011) However, CLPs are a heterogeneous population and it is unclear if 
the inverse effects on B and dendritic cells are due to skewing of progenitors from one 
fate to another, or if the Ly-6D+ CLPs are decreased, thereby biasing the inflammatory 
CLP population towards Ly-6D- CLPs with DC potential.  Together these findings 
suggest that multiple inflammatory factors, including TLR9 and TNFα, reduce bone 
marrow B lymphopoiesis, yet they may not be the same factors directly leading to the 
increase in dendritic cells. In the thymus, both TLR3 and TLR4 high dose stimulation is 
associated with decreased thymic output and decreased DP thymocytes. However, these 
models are associated with very high levels of pro-inflammatory cytokines and 
glucocorticoids, which can also affect thymopoiesis. The direct effect of TLR signaling 
on thymopoiesis remains unclear. (Baron et al., 2008; Billard et al., 2011) 
In summary, prior work in the field has elucidated roles for a variety of cytokines 
in inhibiting murine lymphopoiesis. However, for most cytokines, it remains unclear 
whether they are acting directly on the precursors or on other immune cells. Specific 
roles for TNFα and IL-1 in mediating migration of B cell precursors from the bone 
marrow and inducing myelopoiesis respectively are known to inhibit normal bone 
marrow lymphopoiesis. IL-6 appears to have opposing affects on B lymphopoiesis 
depending on the stage of precursors exposed to IL-6 signaling. Whether or not this is 
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due to changes in the downstream signaling is unclear. Type 1 and 2 interferons are also 
known to affect lymphopoiesis although it is not known which cell type they are acting 
on and whether physiologic amounts that could be seen during inflammation would have 
similar inhibitory effects. TLR signaling also impairs lymphopoiesis but it is not clear at 
which stages of development these inflammatory mediators are acting or whether they are 
acting directly on B and T cell progenitors.  In many of these cases it is also uncertain 
how the inflammation is preventing normal B lymphopoiesis, whether by skewing or 
progenitors away from lymphoid lineages, or by inducing apoptosis or migration from the 
bone marrow.   
 
Our model of systemic inflammation 
In our model of systemic inflammation, we inject mice repeatedly with CpG, the 
TLR9 agonist, five times over the course of ten days (Figure 1). These mice develop 
systemic inflammation including splenomegaly, hepatitis, weight loss and pancytopenias, 
specifically including decreased lymphocyte counts. By using genetically modified 
knockout mice, we are able to characterize the direct effects of TLR9 and IFN-γ on B and 
T lymphopoiesis at multiple stages of development in vitro and in our in vivo model of 
cytokine storm. Since many infectious and autoimmune syndromes result in sustained 
TLR9 stimulation and IFN-γ production, understanding the effects of hyperinflammation 
on hematopoiesis is important for questions of pathogenesis as well as development of 
possible therapeutic interventions to restore homeostasis. 
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Chapter 2 
Materials and Methods 
 
Mice. 
6 week to 12 week old mice were used throughout these studies. No differences in 
sex or age were noted across experiments.  C57BL6, C57BL/6.SJL IFN-γKO and IFN-
γRKO mice were obtained form Jackson Laboratories. TLR9KO and IFN-αRKO mice 
were used as previously described and bred in our colony. (Hemmi et al., 2000; Leitner et 
al., 2006) Bone marrow chimeras were administered 950 greys of gamma irradiation 
followed by intravenous injection of 4-7 million bone marrow cells. Chimeric mice were 
allowed 10 weeks to rest before use in experiments. Mice were maintained at the 
University of Pennsylvania and Children’s Hospital of Philadelphia animal facilities. All 
procedures were performed with consent from institutional ethics boards. 
 
Antibodies and flow cytometry. 
The lineage panel included antibodies against TCRβ, CD3, CD19, B220, NK1.1, 
CD11c, CD11b, GR-1 (Ly-6C and Ly-6G), Ter119, FcεR, and CD8α. Aqua live dead 
was used to visualize dead cells. All populations were first gated on forward and size 
scatter to limit dead cells and doublets. Samples were then gated as Aqua low for live 
cells. Antibodies were obtained from Biolegend, eBioscience, and BD Biosciences. Cells 
were run on LSRII/II or FACS Aria sorters at the University of Pennsylvania flow 
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cytometry core. FACS data were analyzed using FlowJo software. 
 
 
Mouse models and isolation of samples. 
Mice were injected intraperitoneally on days 0, 2, 4, 7, and 9 with phosphate 
buffered saline (PBS), 50µg CpG 1826 (synthesized by IDT), or 10ηg IFN-γ (peprotech) 
in 200 or 100µl of volume. On day 10 mice were euthanized and organs were taken for 
analysis. In the 4-day model, mice were injected with PBS or 50µg CpG on days 0, 1, 2 
and 3 and taken down on day 4. In the single dose model, mice were injected with PBS or 
100µg CpG and taken down 48hrs later. In the LCMV-Armstrong model, mice were 
infected with 2x105 plaque forming units and taken down 8 days later. All injections were 
performed intraperitoneally. Two tibias and femurs per mouse were flushed using a 27.5 
gauge needle with cold PBS. To ensure full and equal removal of cells, bones were 
dissected open and any remaining cells were flushed out. Red blood cells were lysed 
using ammonium chloride-potassium bicarbonate lysis buffer. Thymi were removed by 
careful dissection and dissociated using fine-tipped forceps and vigorous pipetting with 
cold PBS. 
 
in vitro culture assays. 
OP9 and OP9-dl1 stromal cells were used essentially as described. (Cho et al., 
1999; Schmitt and Zuniga-Pflucker, 2006) Both B and T cell cultures were supplemented 
with 10 ηg/ml of IL-7, Flt3l, and stem cell factor (SCF) (peprotech). For dendritic cell 
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cultures, wells were supplemented with 1 ηg/ml IL-7, 100ηg/ml Flt3l, and 10ηg/ml SCF. 
OP9 and OP9-dl1 cells were plated at 20,00 cells/ml on day -2 and irradiated with 25 
grey gamma irradiation on day 0. Stromal cells rested for 2-6 hours before media was 
changed and 500 CLPs or 1000 Pro or Pre B cells were plated per well. Ly-6D+, Pro, and 
Pre B cell co-cultures were allowed to grow untouched for 7-9 days and Ly-6D- co-
cultures for 13-15 days. Dendritic cell cultures were taken down on day 8. When used, 
CpG was administered at 0.6µg/ml and IFN-γ at 100ρg/ml to individual cultures. Cell 
numbers from OP9 experiments represent the number of events collected per volume per 
time for a given well to allow for comparison. 
 
Statistical Analyses. 
Student’s t-tests were performed for all single comparisons. For data with 
multiple comparisons, 1-way ANOVAs were performed with post-hoc analyses. For data 
comparing two independent variables, 2-way ANOVAs were performed using Prism 
software. 
 
Affymetrix Microarray. 
Mice were treated with PBS (n=3) of CpG (n=3) as described above. On day 10 
Ly-6D- and Ly-6D+ CLPs were sorted separately from each mouse directly into lysis 
buffer from the Qiagen RNAeasy Micro kit Plus using a FACS Aria. Ribonucleic acid 
(RNA) isolation was performed in accordance with the Qiagen protocol. RNA was 
purified using the (deoxyribonucleic acid (DNA)se treatment kit from Qiagen. Further 
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analysis and processing of the RNA for quality, amplification and hybridization to the 
mouse Affymetrix ST 2.0 Chip were performed by the NAPcore at the Children’s 
Hospital of Philadelphia as previously described. (Canna et al., 2014) Microarray data 
have been uploaded to the Gene Expression Omnibus repository (GEO accession number 
will be provided upon acceptance). The array dataset was modeled using a 2-way 
comparison of the Ly-6D- versus Ly-6D+ and PBS versus CpG. Principle component 
analysis was performed using Partek Genomics Suite. Genome-wide significant genes 
from the Ly-6D- PBS vs. CpG comparison were analyzed with the Ingenuity Pathway 
Analysis program using a cutoff of a p value less than 0.00001 and an absolute value Z 
score greater than or equal to 2. 
 
Quantitative real-time polymerase chain reaction (qRTPCR) 
Mice were treated with PBS (n=3) or CpG (n=3) and RNA was isolated from 
sorted CLPs as described above. cDNA was made according to manufacturers 
instructions (Superscript III First-Strand Synthesis System, Invitrogen). qRTPCR was 
performed using the LifeTechnologies protocol. Primers were obtained from Applied 
Biosciences. Real time PCR reactions were done using an ABI700 sequence detection 
system and the 2XSYBR green master mix according to the manufacturer’s 
specifications. The delta-delta CT method was used to quantify results. Values for each 
gene were normalized to β -actin and one of the PBS treated samples for fold change 
comparison.  
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Chapter 3. 
Systemic inflammation impairs lymphopoiesis 
 
Introduction 
While it is known that hematopoiesis is altered during severe inflammation, we 
wanted to pursue how IFN-γ and TLR9 alter B and T lymphopoiesis. Our lab has two 
models of systemic inflammation. One involves TLR9 stimulation by CpG, and the other 
involves LCMV-Armstrong infection of perforin null mice. 
In our primary model, mice are stimulated with CpG 5 times over the course of 10 
days. These mice develop the signs and symptoms of cytokine storm disorders including 
peripheral pancytopenias, splenomegaly, hepatitis, and weight loss but do not become 
moribund or require euthanasia. (Behrens et al., 2011; Canna et al., 2014; Canna et al., 
2013) Prior work from our lab has characterized the serum cytokine levels and found that 
IFN-γ, IL-12, IL-6, and type 1 interferons are produced as well as the anti-inflammatory 
cytokine IL-10.34, 36 We also wanted to know if shorter courses of CpG could result in 
similar alterations in hematopoiesis, as the longer model may produce excess 
inflammation thereby complicating the roles individual factors play in directly mediating 
decreased lymphopoiesis. The comparison of shorter and longer models may also reveal 
whether inflammation is acting at multiple stages across development since it takes time 
for early progenitors to move through lymphoid developmental stages. We therefore also 
gave doses of CpG every day for 4 days as well as a larger, single dose to different 
cohorts of mice. 
 
20 
 
The second model involves infection of perforin null mice with LCMV-
Armstrong. While normal WT mice can clear this infection, these knockout mice are 
unable to kill infected cells and therefore are cannot shut down the immune response. 
These mice develop many of the same signs and symptoms as repeated CpG administered 
mice, yet to a larger degree. In fact, many of these mice lose too much weight or become 
moribund and require euthanasia. While LCMV is an RNA virus and therefore does not 
signal through TLR9, it stimulates other TLRs resulting in very high levels of type 1 and 
2 interferons. (Pien et al., 2002; Wherry et al., 2007) Because LCMV is a live viral 
infection; it induces inflammation through multiple immunologic receptors in addition to 
TLRs. (Jung et al., 2008) Since LCMV infection results in fulminant inflammation, the 
stress response is activated producing glucocorticoids, which contribute to alterations in 
hematopoiesis, specifically reductions in lymphopoiesis. 
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Chapter 3 
Results 
 
Repeated CpG inhibits the developing B and T cell compartments. 
We first induced sustained TLR9 driven inflammation in mice over a 10-day 
period as previously described. (Behrens et al., 2011; Canna et al., 2014; Canna et al., 
2013) On day 10, we examined the bone marrow and found decreased total cellularity 
(Figure 2A). Interestingly, this was driven primarily by a reduction in the CD19+ and 
erythroblast compartments while other lineages were grossly intact (Figure 2B and data 
not shown). This suggests that repeated CpG induced inflammation is not affecting gross 
hematopoiesis, but that it is acting directly on the B cell lineage. As the B cell 
compartment in the bone marrow includes both mature recirculating B cells as well as 
immature developing cells, we further analyzed the B cell compartment and found that 
Pre, Pro, and Immature B cells were all decreased approximately 10-fold in the mice 
receiving CpG compared to PBS treated controls (Figure 2C). As all stages of committed 
B cell precursors were down, we looked one stage earlier at the CLPs and found that the 
lymphocyte antigen 6 complex locus D (Ly-6D) negative, or uncommitted CLPs were 
relatively normal in number, but the Ly-6D+, or B cell committed CLPs were 
significantly decreased (Figure 2C). We therefore also wanted to know if there would be 
a similar effect in T lymphopoiesis since B and T cells develop from the same early 
progenitors and are susceptible to many of the same insults. We found that thymic 
cellularity was also significantly decreased (Figure 3A). Since many stressors specifically 
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alter the DP stage of thymic development, we characterized thymocyte numbers based on 
CD4, CD8, cKit, and CD25 expression and found that all stages were decreased without 
any obvious blocks in development (Figure 3B). Concurrent decreases in T and B 
lymphopoiesis could be due to alterations in early lymphoid development that are carried 
through both lineages, or it could be due to inflammatory factors acting separately on 
both lineages. 
 
4 day CpG diminishes B and T cell lymphopoiesis. 
In our 10-day model it is possible for decreases in early stages of hematopoiesis to 
carry through into later stages. We therefore wanted to look in a shorter model of CpG 
induced inflammation for similar or lessened changes in B and T cell development. First, 
we wanted to ensure that total bone marrow changes mimicked those found in the 10-day 
model. To test this we injected mice with CpG 4 on consecutive days and took down the 
mice on day 5. We found similar reductions in total bone marrow cellularity to the 10-day 
model (Figure 4A), which was also primarily driven by decreases in the B cell 
compartment (Figure 4B). Within 4 days, a lone defect in the CLP compartment should 
not lead to 10 fold decreases in Immature B cells like in the 10 day model. To test if this 
was the case, we looked at B cell precursor numbers in these mice and found that unlike 
the 10-day model, only Pre and Immature B cells were significantly decreased (Figure 
4C). This suggests that the CpG induced inflammatory environment can act at the later 
stages of bone marrow B cell development. Thymic cell counts were also similarly 
decreased (Figure 4D), suggesting that the factors driving decreased Pre and Immature B 
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cells and T cells in the 10 day model are induced within 4 days and do not require 
protracted dosing to mediate their effects. The factors affecting the CLPs, however, do 
require a longer dosing protocol. 
 
Single dose CpG diminishes myeloid, not lymphoid compartments. 
As four consecutive doses sufficiently impaired the lymphoid compartments, we 
wanted to know if a single dose would have similar effects. We therefore gave one larger 
dose of CpG and looked 48 hours later at the bone marrow and thymus. While total bone 
marrow cellularity was still decreased (Figure 5A), surprisingly this was due to 
diminished myeloid compartments, as the number of B cells did not change (Figure 5B). 
Thymic cellularity was also not significantly decreased (Figure 5C). Together this 
suggests that the single dose of CpG was not sufficient to alter lymphopoiesis in the same 
manner as in a sustained CpG model. 
 
LCMV induced cytokine storm severely impairs the bone marrow and thymic 
compartments. 
We then wanted to test whether the bone marrow and thymic compartments were 
altered in the more severe inflammatory environment of uncontrolled infection. Perforin 
null mice were infected with LCMV-Armstrong and taken down on day 8 corresponding 
to the peak of the immune response in LCMV infected WT mice. Unfortunately, one 
infected mouse was too sick and did not survive until day 8 preventing statistical analysis 
for significance. When we looked at the bone marrow counts in the surviving mice, we 
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found that bone marrow cellularity was decreased and that the B cell compartment was 
severely inhibited (Figures 6A and 6B). We again looked at the thymus for reductions in 
thymopoiesis and found severely decreased thymic cellularity (Figure 6C). These 
findings suggest that LCMV induced cytokine storm inflammation impairs thymic 
development and inhibits the B cell compartment in the bone marrow. 
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Chapter 3 
Discussion 
 
Using various models and dosing methods, we have shown that lymphopoiesis is 
inhibited during systemic inflammation. Interestingly, these data suggest that the 
inflammatory environment is acting at multiple stages of B lymphopoiesis. It is reducing 
numbers of Ly-6D+ CLPs, the earliest known stage of B cell commitment as well as 
acting at the Pre and Immature B cell stages as evidenced in our 4 day CpG model. 
Insults at each stage of development can also account for why Ly-6D+ CLPs decrease 2-
fold while Pro, Pre, and Immature B cells decrease 10-fold. Generally, small decreases in 
early progenitors can be compensated for by the proliferative burst during later stages of 
development. Our data suggest that the inflammatory environment is inhibiting lineage 
development, blocking proliferation, or inducing apoptosis of progenitor cells. 
Surprisingly, single dose CpG lead to significant reductions in myeloid populations but 
not lymphoid populations in our model. This suggests that repeated TLR9 stimulation 
induces unique factors that mediate lymphopoiesis. 
As developing T cells are also reduced, factors could be acting early in lymphoid 
development inhibiting both lineages. However, similar to B cells, reductions in early T 
cell progenitors can be compensated for by the large proliferative capacity of the cells 
that reach the thymus. (Zlotoff et al., 2010) While homing may also be affected during 
inflammation, decreases across development suggest that there are alterations in the 
thymic stromal compartments, such as is seen during systemic irradiation. (Zhang et al., 
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2014b; Zlotoff et al., 2011) 
TLR9 stimulation produces a number of cytokines and it is possible that different 
factors are acting at the various stages of B lymphopoiesis. The roles of TLR9 and IFN-γ 
will be discussed in more depth in chapter 2. It is possible however, that type 1 
interferons, IL-6, and TNFα could be contributing to the decreases seen in our model. 
One possibility is that TNFα is reducing levels of CXCL12 that retains progenitors in the 
bone marrow, thereby allowing them to migrate to the spleen. We however see decreased 
total numbers of splenic B cells (data not shown), suggesting that this is not the only 
explanation for the decrease in bone marrow B lymphopoiesis. Additionally, as thymic 
subsets are equally decreased across development, it would suggest that TNFα is not 
directly inhibiting CD25 expression or DP thymocyte development. Type 1 interferons 
are also produced in our model and can diminish erythropoiesis as well as myelopoiesis 
and lymphopoiesis. (Binder et al., 1997; Buechler et al., 2013) While we do see reduced 
erythrocyte progenitors in the bone marrow of mice receiving repeated CpG, myeloid 
populations are stable. Even though erythropoiesis is reduced in the bone marrow, it is 
increased in the spleen and liver. Most of the extra-medullary hematopoiesis seen in the 
spleens of our mice is in fact due to increased erythroblasts (data not shown). These 
findings suggest that high dose type 1 interferons are not the sole factors mediating the 
decrease in our models of inflammation. IL-6 is also produced in our model and may be 
acting at the early stages of lymphopoiesis where it can diminish lymphoid potential. 
(Maeda et al., 2005; Maeda et al., 2009; Maeda et al., 2010) It is unlikely the main 
contributing factor, however, as it would increase later B progenitors in contrast to our 
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data. 
Severe inflammation acts as a stressor to the body producing steroid hormones 
called glucocorticoids. At high doses, these steroid hormones have profound anti-
lymphopoiesis effects. In B lymphopoiesis they are known to act primarily at the Pro and 
Pre B cell stages as the cells undergo selection. (Andreau et al., 1998; Gruver-Yates et al., 
2014; Igarashi et al., 2005) This is also true in the thymus, where steroids have potent 
effects inhibiting DP thymocytes that are undergoing positive selection. (Brewer et al., 
2002; Lu et al., 2000) While it is possible that steroids are contributing to the effects we 
see in our CpG model, the decrease in CLPs and thymocytes across development suggest 
they are not the sole factors blocking lymphopoiesis. 
It is possible that TLR9 signaling alone drives these reductions in B 
lymphopoiesis as all progenitors express TLR9. (Welner et al., 2008) However, we see 
similar decreases in B cell precursors in perforin null mice infected with LCMV 
suggesting that other TLRs and the broad inflammatory environment can also inhibit 
lymphopoiesis. As LCMV is an RNA virus, it stimulates TLR3, TLR7 and TLR8, of 
which TLR7 is expressed on lymphoid progenitors. (Sioud et al., 2006) LCMV infection 
does produce high levels of IFN-γ, which is similar to our CpG model. Since LCMV 
infection is a much stronger stressor than repeated CpG dosing, it is likely that steroids 
are also playing a larger inhibitory role in this model. 
Overall, these data suggest that CpG induced inflammation acts at multiple stages 
of B cell development while also inhibiting T cell development. This may be occurring 
by multiple mechanisms, including skewing of early progenitors away from the B 
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lineage, decreased proliferation at the Pre B cell and DP thymocyte stages and increased 
apoptosis. As thymopoiesis is also impaired, it suggests that global lymphoid 
development may be diminished or that inflammatory factors act independently after 
progenitors commit to separate lineages. Most likely, inflammation is doing both because 
it acts at early and later stages of development. The decreases at multiple stages of 
development are likely due to various inflammatory factors, including TLR9 signaling 
itself, IFN-γ, type 1 interferons, IL-6, and TNFα. 
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Chapter 4 
TLR9 and IFNγR signaling directly impair B lymphopoiesis 
 
Introduction 
Early hematopoietic cells including CLPs and developing B cells are known to 
express high levels of TLR9. (Welner et al., 2008) Data from Paul Kincaide’s lab 
suggests that TLR9 stimulation of CLPs may divert these progenitors away from the B 
cell lineage and towards the dendritic cell lineage. (Welner et al., 2008) While the CLP 
population used in that paper is heterogeneous including both Ly-6D- and B cell 
committed Ly-6D+ CLPs, it shows that CLPs can receive instructive signals through their 
TLRs.  We do know that the decrease in lymphopoiesis is dependent on global CpG 
signaling through TLR9, as TLR9 null mice do not develop the signs of systemic 
inflammation nor do they have decreased B or T lymphopoiesis (data not shown). It is 
unclear however, whether TLR9 must signal on the lymphoid progenitors themselves or 
whether it is signaling on other cells to release secondary factors that then mediate the 
decreases in lymphopoiesis. 
One candidate factor is IFN-γ. Our lab has also shown that IFN-γ is essential for 
the full spectrum of disease to develop, as IFN-γR knockout (IFN-γRKO) mice are 
protected from developing widespread inflammation and do not produce the array of 
cytokines listed above.34, 36 The IFN-γ receptor is a heterodimer of two subunits, IFN-γR1 
and IFN-γR2. (Bernabei et al., 2001; Jung et al., 1987) IFN-γR1 is expressed almost 
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ubiquitously in the immune system, while IFN-γR2 is expressed on subsets of myeloid 
cells, B cells, stromal cells and certain populations of T cells. (Gazit et al., 2013) Both 
subunits are expressed on CLPs and B precursors. Early thymocyte precursors also 
express IFN-γR, but decrease expression during thymic development until cells reach the 
single positive stages. (Mingueneau et al., 2013) As stromal cells also express the IFN-
γR, it is possible that IFN-γ is directly acting to inhibit stromal cell release of cytokines 
necessary to promote development. (Stagg et al., 2006) 
In myeloid cells, it is well documented that TLR and IFN-γR signals can interact 
and enhance the cellular response to either stimuli. In macrophages, IFN-γ exposure 
primes cells to respond to TLR4 signaling. (Chen and Ivashkiv, 2010; Franklin et al., 
2009; Hu et al., 2008) IFN-γ priming causes less production of the anti-inflammatory 
factor IL-10 and excess production of TNFα, IL-6, and IL-12. This occurs by a variety of 
mechanisms, including increased expression of TLRs, enhanced downstream signaling, 
as well as epigenetic modulation leading to increased and prolonged recruitment of TLR 
signaling molecules to the promoters of inflammatory genes. Perhaps sustained TLR 
signaling and IFN-γ production are required to drive the decreases in B lymphopoiesis, 
which is why a single dose is insufficient compared to 4 or 10 days of dosing. It is 
possible that IFN-γR and TLR9 signaling are acting synergistically directly at the level of 
the lymphoid progenitors or on peripheral cells to produce a secondary mediator that 
decreases B and T lymphopoiesis. We therefore assayed the roles of TLR9 and IFN-γR 
signaling play in inhibiting B lymphopoiesis by using in vitro and in vivo models. 
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Chapter 4 
Results 
 
CpG and IFN-γ stimulation differentially affect B and T cell growth in vitro. 
As B cell precursors express both TLR9 and IFN-γR, we investigated which B 
cell progenitors were affected by CpG and IFN-γ treatment using the established OP9 co-
culture system to eliminate confounding factors that may be present in vivo. (Cho et al., 
1999; Schmitt and Zuniga-Pflucker, 2006) Ly-6D- CLPs, Ly-6D+ CLPs, Pro, or Pre B 
cells were cultured in B cell promoting conditions and administered PBS, CpG, or IFN-γ. 
We found significant reductions in the number of B cells generated from Ly-6D+ CLPs, 
Pro and Pre B cells that received CpG or IFN-γ compared to PBS (Figure 7A). To test if 
treatment effects were specific to the B cell lineage, CLPs were also cultured in T cell 
promoting conditions. Surprisingly, Ly-6D- CLPs receiving CpG yielded more T cell 
precursors while IFN-γ still severely decreased T cell yields (Figure 7B). This suggests 
that CpG and IFN-γ are acting via different pathways to alter CLP development. 
 
TLR9 signaling directly inhibits B cell differentiation but increases T cell 
differentiation in vitro. 
To interrogate whether the CpG induced inhibition of B lymphopoiesis was acting 
in a TLR9 intrinsic manner, we performed similar in vitro experiments using mixed 
cultures of equal numbers of TLR9 sufficient and TLR9 deficient (TLR9KO) CLPs.  In 
the B cell promoting conditions, we found that only the TLR9 sufficient progenitors 
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produced lower B cell yields while the TLR9KO cells yielded similar numbers in the 
PBS and CpG treated groups (Figure 8A). We performed the same experiment in T cell 
promoting conditions and found that only the TLR9 sufficient CLPs led to increased T 
cell yields with CpG treatment, suggesting that TLR9 signaling directly alters the lineage 
potential of CLPs (Figure 8B). 
 
TLR9 extrinsic factors contribute to the decrease of B lymphopoiesis in vivo. 
To determine if TLR9 signaling was the primary cause of the lymphopoiesis 
defects in vivo, we made mixed bone marrow chimeras. We injected lethally irradiated 
TLR9KO hosts with mixed 50:50 congenically marked WT/TLR9KO bone marrow and 
waited 10 weeks for reconstitution before administering the 10-day CpG regimen.  In 
contrast to the in vitro data, we found that the TLR9KO B cell progenitors were not 
spared, as Pre B cell numbers from mixed chimeras receiving CpG demonstrated similar 
decreases in numbers of both wild type (WT) and TLR9KO precursors (Figure 9A). Pro 
and Immature B cells yielded similar results to the Pre B cells (data not shown). This 
suggests that in vivo, TLR9 intrinsic signaling does not decrease lymphopoiesis or that 
the contribution of other TLR9 extrinsic factors mask the role of TLR9. While the 
thymocyte data demonstrated an upward trend in numbers of cells seeing TLR9 
stimulation, the changes were not significant suggesting that other factors are also acting 
on thymopoiesis in vivo. These factors, including IFN-γ, may be inhibiting thymopoiesis 
thereby masking a TLR9 intrinsic effect (Figure 9B). 
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Type 2 but not type 1 interferons mediate decreases in lymphopoiesis. 
Because IFN-γ is induced by in vivo TLR9 stimulation and it inhibited CLP 
differentiation in vitro (Figure 7), we investigated whether IFN-γ was contributing to B 
and T lymphopoiesis defects in vivo.  We injected WT or IFN-γRKO mice with CpG or 
PBS and found that the IFN-γRKO mice were protected from inflammation as they had 
significantly smaller decreases in B cell progenitors compared to WT mice (Figure 10A). 
This suggests that IFN-γ is one of the main mediators leading to decreased B cell 
progenitors in vivo.  It may be the confounding factor responsible for masking the TLR9 
intrinsic effect. This is not true of all TLR9 induced cytokines, as mice lacking the IFN-α 
receptor gene (IFN-αRKO) were not protected compared to the WT mice (Figure 10B). 
The restoration of B cell precursors in IFN-γRKO mice was not complete, suggesting that 
other signals also contribute to the defects in B lymphopoiesis. Thymic cellularity, in 
contrast to B lymphopoiesis, was not dependent on type 1 or 2 interferons since both 
IFN-αRKO and IFN-γRKO mutant mice had statistically similar decreases compared to 
PBS controls, and the interaction coefficient was not significant (Figures 10C and D). 
This suggests that B and T lymphopoiesis are differentially regulated by interferons. 
 
Interferon gamma receptor signaling directly inhibits Ly-6D+ CLP development in 
vitro. 
To test if the decreases we saw in vitro with IFN-γ administration were IFN-γR 
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precursor cell intrinsic, we used the same mixed culture strategy as before but with WT 
and IFN-γRKO cells and IFN-γ administration. In these mixed cultures, we found that 
only the WT cells yielded fewer B cells in response to IFN-γ, as the IFN-γR KO cell 
yields were similar to cultures receiving PBS (Figure 11A). Since IFN-γ decreased T cell 
yields when added to OP9-dl1 cultures, we wanted to test whether IFN-γ is acting 
directly on the T cell precursors like it was acting on the B cell precursors. Using the 
same mixed strategy as for B cells, we found that only the Ly-6D+ cultures demonstrated 
a IFN-γR intrinsic decrease in T cell yields while both IFN-γRKO and WT cells 
decreased in the Ly-6D- cultures (Figure 11B). Even though Ly-6D+ CLPs do not 
generate T cells in vivo, they can in vitro. These data suggest that Ly-6D+ CLPs are more 
sensitive to IFN-γ than Ly-6D-, and that the OP9-dl1 cells or T cell precursors produce 
factors in response to IFN-γ that also decrease T lymphopoiesis.  
 
Interferon gamma receptor signaling directly inhibits B cell development in vivo. 
We then investigated whether a cell intrinsic IFN-γR response is the dominant 
force leading to decreased B cell progenitors in vivo by making mixed IFN-γRKO and 
WT congenically marked bone marrow chimeras. We used a 90% WT and 10% IFN-
γRKO mix since mice generated with fewer IFN-γ responsive cells do not generate the 
full panel of cytokines normally seen in the sustained TLR9 inflammation model 
(unpublished observations). We found that there was a statistically significant differential 
in Pre B cell numbers in the CpG treated mice such that the IFN-γRKO B cells were less 
affected than WT (Figure 12A). This suggests that there is a measurable cell intrinsic 
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IFN-γR signaling event leading to decreased B lymphopoiesis during sustained TLR9 
inflammation in vivo. Consistent with the results from the IFN-γRKO experiments 
(Figure 10A), the IFN-γRKO cells in the chimeras also trended towards a smaller 
decrease, emphasizing that IFN-yR signaling is not the only factor leading to decreased B 
lymphopoiesis and perhaps unmasking a TLR9 effect. 
 
IFN-γ and CpG act via distinct pathways to inhibit B lymphopoiesis in vivo. 
Given that there appear to be different TLR9 and IFN-γR effects on B cell 
development in vitro, we next investigated whether these two pathways interact in vivo, 
particularly since previous work in innate cells found that IFN-γR and TLR9 signaling 
can synergize at the epigenetic level. (Chen and Ivashkiv, 2010; Hu et al., 2008; Qiao et 
al., 2013) To address this question, we used IFN-γ deficient mice (IFN-γKO), that are 
capable of responding to IFN-γ but are unable to produce it, and examined how CpG, 
IFN-γ or the combination of both stimuli affect B and T lymphopoiesis. The dose of IFN-
γ was selected to replicate serum levels of IFN-γ seen in WT mice treated with the 
repeated CpG protocol. (Behrens et al., 2011) We observed that both CpG and IFN-γ are 
capable of to reducing Pre B cell and thymocyte numbers (Figure 12B).  However, 
statistical modeling did not reveal a significant interaction effect, suggesting that they are 
acting independently via additive and not synergistic pathways, corroborating our in vitro 
data. 
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Chapter 4 
Discussion 
 
Our data demonstrate that TLR9 has disparate effects on the B and T cell 
lineages, impairing early progenitors from becoming B cells, yet enhancing their ability 
to become T cells in vitro. One possibility is that TLR9 is acting at the level of the CLP 
to skew precursors away from the B cell lineage, and perhaps towards the T cell lineage. 
This may be intrinsic to each CLP or a result of general skewing of the population 
towards CLPs with greater T cell potential since those with greater B cell potential are 
decreased. As CpG also had inhibitory effects on plated Pre B cells, it suggests that it also 
induces apoptosis or inhibits proliferation in later progenitors. This is in contrast to TLR9 
signaling on mature B cells, which promotes maturation and induces proliferation. 
(Guerrier et al., 2012) The differential effects of TLR9 on immature versus mature B 
cells may be due to alterations in downstream signaling molecules or epigenetic changes 
allowing TLR9 signaling factors to promote different outcomes. This differential 
signaling is not unheard of, as immature B cells receiving signals through their BCR 
undergo apoptosis while mature B cells are activated and undergo proliferation. 
IFN-γ in contrast, had devastating effects on both B and T cell cultures of CLPs 
suggesting that it is inducing apoptosis or preventing proliferation regardless of exposure 
to B or T instructive signals. It had similar results on plated Pre B cells suggesting that 
IFN-γ signaling effects do not change as the progenitors mature. Perhaps this strong IFN-
γ effect overwhelms the ability to detect an intrinsic TLR9 role in vivo in the mixed bone 
 
42 
marrow chimera system. Surprisingly, even though type 2 interferons directly reduced B 
lymphopoiesis, type 1 interferons did not. While type 1 and 2 interferons share similar 
downstream signaling factors, IFN-γ is much more highly expressed in our model, which 
may account for its dominating effects in vivo. (Canna et al., 2014; Canna et al., 2013) 
IFN-αRKO null mice do however show slightly improved measures of systemic disease 
including weight loss and anemia. (Canna et al., 2013) This suggests that Type 1 
interferons are important for some aspects of inflammation, (Canna et al., 2014; Canna et 
al., 2013) but may play a redundant role with IFN-γ in mediating decreased B 
lymphopoiesis. 
Interestingly, while TLR9 and IFN-γ are known to act via synergistic pathways in 
macrophages, our statistical modeling data suggest that they are acting independently to 
inhibit B lymphopoiesis. This is supported by our in vitro data where TLR9 signaling 
encourages T cell development but IFN-γ inhibits both T and B cell development. TLR9 
signaling appears to skew CLPs away from the B cell lineage while IFN-γ solely acts to 
induce apoptosis or block proliferation. It may be possible that the common sites where 
synergism is observed in myeloid cells, promoters of TNFα and IL-6 for example, are not 
transcriptionally active in these early progenitors or are not main contributors responsible 
for decreasing lymphopoiesis. 
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Chapter 5 
Introduction 
 
The ability of TLR9 to enhance T cell potential but inhibit B cell potential 
suggests that transcriptional changes may be are occurring within these progenitors 
altering their lineage potential. Early hematopoiesis relies on complex interactions of 
various transcription factors important for directing cells towards specific lineages. 
Hoxa9 is a homeobox transcription factor important for early hematopoiesis. Hoxa9 null 
mice exhibit lower numbers of peripheral myeloid and lymphoid cells. They also have 
reduced clonogenic potential for erythroid and myeloid colony types with even larger 
reductions in B cell outputs from lymphoid colonies. (Lawrence et al., 1997) One key 
aspect of Hoxa9’s regulation of lymphopoiesis is control of Flt3 expression. (Gwin et al., 
2010) Hoxa9 null mice have very low levels of FLt3 expression, which accounts for part 
of the reductions in lymphoid cells. (Gwin et al., 2013b) Hoxa9 is highly expressed at the 
Ly-6D- CLP stage where it turns on genes important for B cell specification before 
turning off allowing for further development. (Gwin et al., 2013a; Gwin et al., 2010; 
Gwin et al., 2013b) Spleen focus forming virus pro-viral integration oncogene (Pu.1) is 
another transcription factor important in hematopoiesis. Pu.1 mutant mice have normal 
numbers of megakaryocytes and erythroid progenitors but display a multilineage defect 
in myeloid and lymphoid lineages. (Scott et al., 1994) Pu.1 also controls expression of 
IL-7Rα and is required for the generation of Pro B cells. (DeKoter et al., 2002) Another 
transcription factor expressed early during development is Ikaros. Ikaros proteins act as 
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transcriptional repressors and activators and in lymphoid progenitors contribute to 
upregulation of Flt3 and IL-7Rα. (Georgopoulos et al., 1994) Ikaros mutant mice have 
normal myeloid erythroid formation yet lack T, B, and NK cells as well as common 
lymphoid progenitors .(Georgopoulos et al., 1994) 
Once these early regulating transcription factors upregulate expression of Flt3 and 
IL-7Rα, cells are directed towards the lymphoid fates retaining minimal myeloid 
potential. Expression of E12 and E47, collectively known as E2A, is essential for B cell 
development as E2A mutant mice have intact peripheral myeloid and T cell populations 
but absent peripheral B cells and low numbers of CLPs. (Bain et al., 1994) E2A is also an 
important regulator of IL-7Rα, which together turn on the transcription factor EBF-1. 
(Seet et al., 2004; Tsapogas et al., 2011) EBF-1 plays a central role in B lineage 
specification, regulating many of the genes associated with the B cell receptor and 
immunoglobulin heavy chain recombination. (Lin and Grosschedl, 1995) While EBF-1 
specifies the B cell fate, its induction of the transcription factor Pax5 solidifies B cell 
commitment as Pax5 over-expressing cells can no longer generate T cells or 
macrophages, (Souabni et al., 2002) and Pax5 mutant Pro B cells maintain multilineage 
potential. (Nutt et al., 1999; Rolink et al., 1999) 
Many of the same early genes important for B lymphoid development are 
important for T cell development including Hoxa9, Pu.1, and Ikaros. One unique issue 
during T cell development is the migration of uncommitted lymphoid precursors from the 
bone marrow to the thymus. (Carlyle and Zuniga-Pflucker, 1998) Successful thymic 
settling requires expression of chemokine receptors including CCR7 and CCR9. (Zlotoff 
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et al., 2010) While loss of CCR7 and CCR9 reduces the numbers of early thymic 
progenitors, total cellularity is near normal due to the large proliferative capacity of cells 
that do successfully enter the thymic environment. (Zlotoff et al., 2010) Once these 
progenitors settle the thymus, high levels of notch signaling instruct the T cell fate and 
block factors important for the B cell and dendritic cell fates including E2A, Pax5, and 
CCAAT/enhancer binding protein α. (De Obaldia et al., 2013; Pongubala et al., 2008; Pui 
et al., 1999; Radtke et al., 1999), 66  Notch1 also induces the transcription factors hairy 
and enhancer of split 1 and T cell factor -1 (TCF1), which silence other cell fates further 
committing precursors to the T cell fate. (De Obaldia et al., 2013; Rapino et al., 2013; 
Tomita et al., 1999; Weber et al., 2011) 
Differentiation into the various subsets of dendritic cells requires either 
granulocyte-macrophage colony stimulating factor or Flt3. Common lymphoid 
progenitors that become DCs primarily become pDCs or lymphoid resident DCs. (Carotta 
et al., 2010) High levels of Flt3 drive dendritic cell differentiation from lymphoid 
precursors. Mice deficient in Flt3 or its downstream signaling molecule signal transducer 
and activator of transcription 3 demonstrate markedly lower lymphoid resident and 
plasmacytoid dendritic cells (pDC). (Kingston et al., 2009) Similar to T and B cells, Pu.1 
and Ikaros play roles in dendritic cell differentiation from lymphoid progenitors. Induced 
deletion of Pu.1 leads to decreased pDCs and conventional DCs (cDC) in part through 
decreased expression of Flt3. (Carotta et al., 2010) Mice expressing low levels of Ikaros 
have decreased peripheral pDCs but normal cDCs also due to an inability to respond to 
Flt3 ligand. (Carotta et al., 2010) Expression of the E protein E2-2 specifies and 
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differentiates dendritic cell precursors to the pDC lineage as E2-2 mutant mice have a 
specific defect in the pDC compartment with normal cDC and B cell numbers. (Cisse et 
al., 2008) Correspondingly, pDCs require lower levels of the protein inhibitor of DNA 
binding 2 (Id2), which is a direct inhibitor of E proteins. Other DC lineages express high 
levels of Id2, corresponding to their low levels of E2-2. (Jackson et al., 2011) E2-2 also 
acts to turn on interferon regulatory factor 8, which induces expression of TLR9 and type 
1 interferons. (Schroder et al., 2007; Tailor et al., 2007) Type 1 interferons in turn further 
promote pDC differentiation from CLPs. (Chen et al., 2013) 
The ability of TLR9 to enhance T cell potential but inhibit B cell potential in our 
model suggests that transcriptional changes may be are occurring within early lymphoid 
progenitors thereby altering their lineage potential. Early hematopoiesis relies on 
complex interactions of various transcription factors important for directing cells towards 
specific lineages.  We wanted to look for alterations in lineage potential of CLPs in our 
CpG treated mice. 
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Chapter 5 
Results 
 
Exposure to CpG induced inflammation in vivo skews CLPs away from the B cell 
lineage and enhances T cell differentiation in vitro. 
To determine if the complex in vivo TLR9 induced inflammatory milieu causes 
lineage skewing, we sorted Ly-6D+ and Ly-6D- CLPs from mice receiving repeated CpG 
or PBS injections and placed them in the OP9 culture system under B, T or dendritic cell 
promoting conditions. No further CpG or inflammatory cytokines were given during the 
in vitro culture process. We found that Ly-6D+ CLPs isolated from CpG treated mice 
yielded significantly fewer B cells than those from the PBS treated mice in B cell 
conditions (Figure 13A).  In contrast, we found that the CLPs exposed to the 
hyperinflammatory environment demonstrated enhanced T cell potential (Figure 13B). 
This may occur in a cell intrinsic manner or by skewing of the population towards CLPs 
that are predisposed to generate T cells. CLPs destined to generate T cells may express 
higher levels of the thymic homing receptors CCR9 and CCR7. To test this we stained for 
CCR9 levels but found lower CCR9 expression on Ly-6D- CLPs form CpG treated mice 
(Figure 13C). To test if the increase in T cell yields was unique to the T cell lineage, we 
also tested DC potential. Ly-6D+ CLPs, while able to differentiate into T cells in vitro 
generated minimal dendritic cells even under dendritic cell promoting conditions. They 
did generate B cells however, which showed similar results to the B cell conditions 
(Figure 14A).  Ly-6D- CLPs gave rise to very few B cells but did generate both pDCs and 
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cDCs (Figure 14B). Surprisingly, exposure to the CpG inflammatory environment did not 
alter DC yields compared to PBS treated mice. 
 
CpG induced inflammation alters the B cell transcriptional program. 
We next assayed the transcriptional program of CLPs during inflammation for 
factors that might explain the skewing away from the B cell lineage. To get a global 
transcriptional view, we analyzed mRNA expression from Ly-6D- and Ly-6D+ CLPs 
from repeated CpG or PBS treated mice by microarray. 3 mice were used per group and 
samples were run individually. Principle component analysis across all 4 groups of 
samples demonstrated that the four groups cluster independently, suggesting different 
transcriptional programs based on both stage of development and the presence of 
inflammation (Figure 15A). In order to look for differentially expressed genes between 
the different groups, we performed a two-way ANOVA. Using a false discovery rate of 
20% (Benjamini-Hochberg), we found 2734 genes differentially expressed in Ly-6D- 
versus Ly-6D+ CLPs and 382 genes differentially expressed between PBS and CpG 
treatments, 225 of which were in both lists (Figure 15B). Thus, approximately 60% 
(225/382) of the genes altered by sustained TLR9 induced inflammation are also genes 
that appeared to be altered during the transition from the Ly-6D- to Ly-6D+ stage of B 
cell development. 
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Ingenuity Pathway Analysis suggests Hoxa9 is down-regulated in Ly-6D- CLPs 
during CpG induced inflammation. 
Focusing on the Ly-6D- CLPs, which have in vivo multi-lineage potential, we 
explored potential factors that could account for the pattern of differentially expressed 
genes between PBS and CpG exposures using the upstream analysis module of the 
Ingenuity Pathway Analysis (IPA) program. We found that the transcription factor Hoxa9 
was predicted to have the most down-regulated activity (Table 1). This was of particular 
interest, as Hoxa9 is described to be an important B cell lineage coordination factor. 
(Gwin et al., 2013a; Gwin et al., 2010; Gwin et al., 2013b; Izon et al., 1998) In contrast, 
we did not find significant evidence suggesting changes in Pu.1, E2A, Ikaros, or E2-2. 
Additionally, in concert with what would be expected from our mouse model, many of 
the predicted up-regulated factors were related to inflammatory cytokines produced in 
our model. 
 
Hoxa9 and EBF-1 are down-regulated in CLPs exposed to CpG induced 
inflammation. 
We then interrogated transcriptional levels of Hoxa9 and some of its targets by 
qRTPCR.  We found that Ly-6D- CLPs from CpG treated mice had lower levels of 
Hoxa9 than their PBS treated counterparts. Known Hoxa9 targets important for B cell 
specification, Flt3, IL-7Rα and RAG1, (Gwin et al., 2013a; Gwin et al., 2010; Gwin et 
al., 2013b; Izon et al., 1998) were also decreased (Figure 16A). As many of these targets 
are also known to be mediated by the transcription factor E2A, we looked at E2A and its 
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unique target FOXO1 but found that neither were significantly decreased 
transcriptionally, suggesting that alterations in Hoxa9 may preferentially account for the 
decreases in Flt3, RAG1, and IL-7Rα in CpG treated mice (Figure 16B). While E2A is 
primarily regulated at the protein level, lack of change in FOXO1 suggests that it is not 
decreased. EBF-1, a target of IL-7Rα and an important factor for initiating the B cell 
program, (Tsapogas et al., 2011) was also decreased in Ly-6D- CLPs, (Figure 16A).  
Together these data suggest that Hoxa9 and EBF-1 are decreased in CpG treated CLPs 
and perhaps account for the skewing away from the B cell lineage. 
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Chapter 5 
Discussion 
 
 The complex inflammatory environment induced by sustained TLR9 activation 
leads to distinct transcriptional programs in CLP populations.  Via both a bioinformatics 
approach and by examining transcript levels, we identified loss of Hoxa9 and its indirect 
target EBF-1 as potential pathways by which inflammation suppresses B lymphopoiesis.  
It is interesting to note that NFkB activation suppresses Hoxa9 transcription in a number 
of different cell types, (Trivedi et al., 2008) consistent with a role for inflammation in this 
process. While Hoxa9 is important for development of other lineages, Hoxa9 mutant 
mice have more profound effects in the B cell pathway. (Lawrence et al., 1997) Since 
EBF-1 is one of the orchestrating factors of the B cell program, its decrease could allow 
for progenitors to remain open to other lineage fates although our data suggest this is 
specific to the T cell and not dendritic cell fates. EBF-1 is normally expressed at high 
levels during the Ly-6D+ stage of B cell differentiation, which may be why it did not 
come out of the pathway analysis program, which was focused on Ly-6D- CLPs. 
 Our data surprisingly suggested that Ly-6D- CLPs exposed to the CpG induced 
inflammatory environment are impaired in their ability to become B cells, enhanced to 
become T cells, and indifferent to become DCs. This may be due to yet unknown 
regulation of genes important for the T cell fate by CpG induced inflammation. In fact, 
when we look at the raw values from the microarray, TCF1 transcripts are significantly 
increased in both Ly-6D- and Ly-6D+ CLPs exposed to CpG induced inflammation (data 
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not shown). This is surprising as Notch1 transcripts were significantly decreased in Ly-
6D- CpG CLPs (data not shown), and Notch induces TCF1 under homeostatic conditions. 
This suggests that there may be factors biasing progenitors towards or against the T and 
B cell fates that are yet unclear and that there is a connection between inflammation and 
induction of TCF1. Perhaps inflammation serves to augment the low level of Notch 
signaling present in the bone marrow. Previous studies have suggested that TLR9 
signaling drives CLPs towards the dendritic cell fate. (Welner et al., 2008) However, 
these studies examined bulk CLPs, and thus the loss of Ly-6D+ CLPs during 
inflammation would skew the bulk CLP population towards the Ly-6D- CLPs that have 
broader differentiation capabilities. This would make it appear as if bulk CLPs have 
greater DC potential. In our report, we separate the Ly-6D- and Ly-6D+ populations 
revealing their true B and DC potentials. This may be due to skewing of individual cells 
away from the B cell fate or from further heterogeneity within the CLP compartment. 
Consistent with our cell culture findings, levels of E2-2 are not significantly changed in 
our array data (data not shown). 
 
 
 
 
59 
 
60 
 
61 
 
62 
 
63 
Table I. Ingenuity Pathway Analysis of Ly-6D- CLPs from CpG and PBS treated 
mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upstream Regulator Activation 
Z-score 
p-value of overlap 
HOXA9 -3.08 5.45e-06 
POR -2.813 1.65e-04 
HOXA7 -2.789 1.49e-07 
RB1 -2.262 3.17e-04 
CD3 -2.076 8.76e-06 
   
IFNγ 3.857 3.71e-07 
CD38 3.536 3.67e-07 
IL5 3.019 5.71e-07 
STAT3 2.954 2.74e-05 
IL6 2.691 1.82e-08 
IL1B 2.673 1.56e-04 
CSF2 2.670 4.23e-05 
IL4 2.638 1.84e-08 
IFN alpha/beta 2.191 3.84e-05 
Ifnar 2.135 3.79e-04 
IKBKB 2.122 1.74e-05 
APP 2.087 1.72e-05 
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Chapter 6 
Future Directions and Discussion 
 
Apoptosis versus proliferation 
While it is known that inflammation alters hematopoiesis, it is unclear if 
individual factors act on the progenitors or on the environment and whether they act at 
multiple stages. In this thesis, we have shown that B and T lymphopoiesis are diminished 
in a cell intrinsic manner by both TLR9 and IFN-γR signaling, and that they act 
independently at multiple stages of development. TLR9 skews early progenitors away 
from the B cell fate towards the T cell as well as decreases Pre B cell numbers in vitro. 
IFN-γ acts independently of CpG, directly decreasing both T and B cells likely at 
multiple stages of development. While CpG does affect lineage determination, it is still 
unclear whether TLR9 and IFN-γR signaling induce apoptosis or reduce proliferation of 
developing cells. In another mouse model, high dose CpG stimulation inhibits Pro B cell 
proliferation by inducing apoptosis. (Lalanne et al., 2010)  Preliminary data from our lab 
found similar rates of apoptotic B cell progenitors by annexin V staining (data not 
shown). While this could be because apoptosis is not a primary factor leading to 
decreased lymphopoiesis, it is also possible that apoptotic cells are cleared too quickly in 
vivo and therefore changes in rates are undetectable. Future work employing other 
methods to detect apoptosis including TUNEL staining for DNA fragmentation may be 
useful in vivo and in in vitro co-cultures. Additionally, if the main cause of decreased 
lymphopoiesis is due to apoptosis, blocking apoptosis should allow cells to overcome this 
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defect. Use of B cell lymphoma (BCL)-xL or BCL-2 transgenic mice the transgene under 
control of lymphoid restricted promoters should shed light on whether apoptosis is a main 
contributor. Proliferation can be tested in vitro by labeling CLPs with carboxyfluorescein 
succinimidyl ester (CFSE) before plating them on OP9 cells. Dilution of CFSE based on 
the number of cell divisions can then be compared between CpG and PBS conditions. 
This method will require optimization as we attempted this once with in vitro CpG 
administration but had poor survival of CLPs after CFSE labeling. Analysis of the few 
surviving cells showed full CFSE dilution between both CpG and PBS treated samples 
suggesting that the surviving cells have normal proliferative capacities (data not shown). 
Feeding mice bromodeoxyuridine (BrdU), a synthetic nucleoside analog of thymidine 
that is incorporated into proliferating cells, would allow for detection of proliferating 
cells in vivo.  Like CFSE, Brdu levels would dilute out every time the cells proliferate 
and can be assayed by flow cytometry using antibodies against BrdU. If CLPs, Pro, and 
Pre B cells have reduced levels of proliferation in CpG treated mice, one would expect to 
see fewer rounds of BrdU dilution. Single cell or liming dilution assays could be used to 
asses changes in cell intrinsic capabilities to become B versus T cells with CpG 
administration in vitro. We attempted these studies but had poor survival of CLPs at 
lower concentrations. Therefore these methods will require further optimization.  
 
Decreased thymic cellularity 
How inflammatory factors mediate the decrease in thymopoiesis in our model is 
unclear. While we see decreased levels of CCR9 on Ly-6D- CLPs from CpG treated 
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mice, a homing defect would not fully account for decreases in thymic subsets across 
development. Homing defects have minimal effects on thymic cellularity, but profound 
effects on early thymic progenitor numbers. (Zlotoff et al., 2010) Therefore, the primary 
contributor to the decrease in total thymic cellularity is likely due to an effect of the 
inflammation on the thymus itself. Recent work looking at the effects of irradiation on 
thymic development has shown that irradiation leads to decreased thymic epithelial cell 
numbers. These thymic epithelial cells are important for producing the chemokines that 
recruit thymic settling progenitors and provide the space required for T cell development. 
Decreased epithelial cells would then lead to decreased homing in addition to downsizing 
the thymic niche so it cannot support normal levels of thymopoiesis. (Zhang et al., 2014b; 
Zlotoff et al., 2011) Decreased epithelial cells could account for the decreased thymocyte 
numbers across all stages of thymopoiesis seen in our model. Future studies 
characterizing the number and transcriptional profiles of thymic epithelial cells during 
inflammation may be useful in determining how thymic cellularity is decreasing and 
whether epithelial cell production of thymic growth factors are altered. 
 
Roles of EBF-1 and Hoxa9 in mediating decreased B lymphopoiesis 
Our work identified the important B cell lineage factors EBF-1 and Hoxa9 as 
being decreased in early progenitors from CpG treated mice. It is unclear which 
inflammatory factors directly mediate the decreases in Hoxa9 and EBF-1. Because TLR9 
signaling had similar effects in vitro, we sorted CLPs from treated TLR9 mixed bone 
marrow chimeras with the intention of looking at EBF-1 and Hoxa9 levels. If TLR9 
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signaling directly leads to these decreases, then only the TLR9 sufficient CLPs in the 
CpG treated mice would have defects in expression. Unfortunately, we are yet unable to 
perform transcriptional analysis due to recovery of low numbers of CLPs. To assess 
whether EBF-1 and Hoxa9 can rescue defects in B lymphopoiesis, future studies 
transfecting bone marrow with EBF-1 or Hoxa9 expressing constructs would be useful. 
These cells could then be used in vitro or to make bone marrow chimeras to assess 
whether forced expression of EBF-1 or HOXa9 restore B lymphopoiesis. EBF-1 turns on 
early in B cell commitment and stays on throughout development. It specifies the B cell 
fate, which may rescue defects associated with potential TLR9 skewing of early 
progenitors away from the B cell lineage. Additionally, as EBF-1 interacts with IL-7, it is 
possible that restoration of EBF-1 levels could improve survival and differentiation of B 
cells and mitigate the effects of inflammation. Control of Hoxa9 expression during 
development is more nuanced, with its peak expression occurring during the Ly-6D- stage 
before turning back off. In fact, over-expression of Hoxa9 leads to suppression of B 
lymphopoiesis. (Thorsteinsdottir et al., 2002) Forced expression of Hoxa9 in CpG and 
PBS treated mice would be difficult but may still be useful when comparing numbers of 
Ly-6D+ CLPs and Pro B cells. 
 
Discussion 
 A multitude of potential factors can induce hyperinflammation leading to 
alterations in hematopoiesis. Depending on the instigating signals and dominating 
cytokines, the resulting inflammation can lead to mobilization of precursors, increased or 
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decreased myelo- or lymphopoiesis, and skewing of progenitors towards different 
populations. While it is known that certain cytokines such as TNFα and IL-1 impact 
lymphopoiesis, our work provides novel insights into how TLR9 driven cytokine storm 
and IFN-γ are acting directly on hematopoietic progenitors at multiple stages of 
development to impair lymphopoiesis. Sustained TLR9 mediated inflammation occurs in 
a number of clinical scenarios such as viral or bacterial sepsis and auto-inflammatory 
disorders including lupus or rheumatoid arthritis.  Immuno-paralysis in sepsis, and B cell 
autoimmunity in lupus may in part arise from dysfunctional B lymphopoiesis. Other 
hyperinflammatory scenarios where IFN-γ is a dominant inflammatory cytokine, such as 
HLH, are associated with B and T lymphopenias and suppression of genes important for 
B lymphopoiesis. (Hinze et al., 2010; Sumegi et al., 2011) As the effects of TLRs and 
inflammatory cytokines signaling on hematopoiesis are better understood, specific 
blocking agents may serve as effective therapeutics to improve bone marrow homeostasis 
in patients during hyperinflammation. 
 It is interesting to speculate why lymphopoiesis is suppressed during 
inflammation.  Emergency myelopoiesis at the expense of lymphopoiesis is well 
described. (Behrens et al., 2011) Mice over-expressing TLR7 develop a lupus-like 
syndrome with high levels of type 1 interferons and increased myelopoiesis in the bone 
marrow and periphery. (Buechler et al., 2013) LPS stimulation of TLR4 causes increased 
myelopoiesis in a stromal cell dependent manner due to high production of granulocyte 
colony-stimulating factor. (Boettcher et al., 2012; Quinton et al., 2002) However, our 
data does not provide evidence of increased bone marrow myelopoiesis. Since we see 
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decreased lymphopoiesis without an increase in myeloid or dendritic cell development, it 
suggests that these are not simply reciprocal functions, but that each is driven by separate 
factors. This is supported by data from other models that show TNFα induces migration 
of B lymphoid progenitors from the marrow whereas IL-1 is required for increased 
myelopoiesis. (Cain et al., 2011; Ueda et al., 2005; Ueda et al., 2004) Further 
characterization of myeloid precursors in the marrow and periphery may shed light on 
whether CpG induced inflammation affects myelopoiesis. 
 If reduced lymphopoiesis is not due to skewing of progenitors towards myeloid 
cell fates, an alternative hypothesis is that shutting down lymphopoiesis is the immune 
system’s attempt to prevent development of autoreactive B and T cells. This may 
especially be relevant with DNA based TLR9 stimulation that leads to nuclear antigen 
reactive B cells. In fact, lupus patients with anti-nuclear antibodies have higher 
percentages of peripheral blood mononuclear cells that express TLR9. TLR9 expression 
also correlates with disease severity. (Klonowska-Szymczyk et al., 2014) TLR9 is 
important for development of anti-DNA antibodies in mice. (Christensen et al., 2005) 
MRL/MPlpr/lpr mice, which are predisposed to developing a lupus-like syndrome due to a 
mutation in Fas, produce significantly less anti-DNA and anti-chromatin antibodies when 
crossed to TLR9 mutant mice. (Christensen et al., 2005) Similar effects are observed in 
lupus mice crossed to TLR7 deficient mice, which develop significantly fewer anti-RNA 
antibodies and produce less type 1 interferons. (Jackson et al., 2014) The role of TLR7 
and TLR9 in promoting development of anti-nucleotide antibodies was found to be B cell 
and not myeloid cells intrinsic expression of TLR7 as conditional TLR knockouts in B 
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cells replicated the findings of straight knockouts crossed to the lupus MRL/MPlpr/lpr 
background. (Jackson et al., 2014) This suggests that preventing B lymphopoiesis during 
TLR stimulation causes the developing population to be skewed away from DNA 
reactive B cells. Long-term experiments monitoring for development of auto-immunity or 
auto-inflammation after exposure to hyperinflammation while open ended, may shed 
light on the consequences of decreased lymphopoiesis during inflammation. Studies 
testing T and B cell repertoires after inflammation may also prove useful in 
understanding whether decreased lymphopoiesis, or prevention by using TLR9 or IFN-γ 
blocking antibodies, alters the repertoires and skews developing cells towards known 
heavy chain usages associated with higher rates of autoimmunity. 
 Because of DNA’s immuno-stimulatory role, CpG is considered a vaccine 
adjuvant. However, its use has yielded mixed results, potentially because of its inhibitory 
roles in lymphopoiesis. Our work suggests that repeated dosing of CpG leads to abnormal 
lymphopoiesis, which may alter the immuno-repertoire.  Sustained decreased in 
lymphopoiesis may compromise the immune system thereby potentially supporting tumor 
growth or infection. In a human phase 1 study using TLR9 agonism to activate cells 
against cutaneous T cell lymphoma, 54% of patients exhibited lymphopenias. (Kim et al., 
2010) Response rates varied depending on the dose of TL9 agonist given with no clear 
correlation between dose and clinical response. In another phase 1 study of CpG as an 
adjuvant for a tumor specific peptide, human telomerase reverse transcriptase, patients 
developed lymphopenia with very low circulating B, NK, and T cell numbers. (Haining et 
al., 2008) Clinical responses in this trial were also varied with few patients exhibiting 
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clear responses to treatment. As mature B cells are tolerant of self-antigens, impaired 
lymphopoiesis due to adjuvant induced inflammation could compromise generation of 
new B cells reactive against the tumor peptide. CpG may act as an appropriate adjuvant 
for certain cancers and infections, yet its actions on lymphopoiesis and ability to induce 
auto-reactive B cells may undermine its effectiveness compared to other adjuvants 
currently in use. 
 CpG treatment is effective in mediating B cell acute lymphoblastic leukemia (B-
ALL) in mouse models. Mice injected with syngeneic B-ALL cells normally die within 
40 days due to tumor burden. However, mice given repeated CpG doses 7 days after 
tumor injection are able to clear the tumor and have near 100% survival at 140 days. 
(Fujii et al., 2007; Seif et al., 2009) This increased survival is in part due to CpG acting 
on innate and lymphoid cells as mice lacking certain arms of the innate immune system 
impaired tumor clearance. (Fujii et al., 2007; Seif et al., 2009) One hypothesis is that 
CpG is acting as an adjuvant for tumor peptides, however, it is also possible that the 
inflammation induced by repeated CpG injections, including type 1 and 2 interferons 
contribute to inhibiting B-ALL growth. 
Not all hyperinflammation is equal. Depending on the cytokines that control the 
inflammatory network, the resulting pathologies can lead to excess stimulation of certain 
arms of the immune system. In particular, certain cytokines decrease hematopoiesis of 
various lineages while some increase production of other lineages or lead to mobilization 
of hematopoiesis from the bone marrow. Prior to the work within this thesis, the roles of 
TLR9 and IFN-γR signaling on lymphopoiesis were unclear. We have shown that 
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hyperinflammation downstream of TLR9 stimulation impairs B and T lymphopoiesis at 
multiple stages of development in part via distinct IFN-γR and TLR9 pathways. TLR9 
acts at the CLP stages skewing progenitors away from the B cell lineage. In contrast IFN-
γ acts on both T and B cell fates diminishing lymphopoiesis. Additionally, our data 
suggest that CLPs exposed to the in vivo inflammatory environment have diminished 
capability to differentiate into B cells even when removed from the inflammation, This is 
possibly due to reduced levels of transcription factors important for B cell development. 
These CLPs are skewed towards the T cell lineage rather than the DC lineage, which 
suggests that the DC lineage is more disparate from the B cell lineage compared to the T 
cell lineage. Together our findings provide insights into the mechanisms that allow 
inflammation and hypercytokinemia to inhibit B and T cell development.  As specific 
cytokine blocking therapeutics continue to have expanded clinical applications, an 
enhanced understanding of how cytokines regulate B cell development in disease will be 
important for predicting efficacy and toxicity of these agents.          
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Appendix 
Abbreviations 
 
B 
 B220, protein tyrosine phosphatase receptor type c 
B-ALL, B cell acute lymphoblastic leukemia  
BCL, B cell lymphoma 
BCR, B cell receptor 
 
C 
 CD, cluster of differentiation  
cDC, conventional dendritic cell 
CFSE, carboxyfluorescein succinimidyl ester 
cKit, stem cell growth factor receptor  
CLP, common lymphoid progenitor 
CXCL, C-X-C motif chemokine ligand   
 
D  
DC, dendritic cell 
Dl1, delta-like 1 
DN, double negative 
DNA, deoxyribonucleic acid  
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DP, double positive 
 
E 
E2A, transcription factor 3 
 EBF-1, early B cell factor 1 
ETP, early thymic progenitor 
 
F 
Flt3, fms related tyrosine kinase 3 
Flt3l, fms related tyrosine kinase 3 ligand 
 
H 
HLH, hemophagocytic lymphohistiocytosis 
HOXa9, homeobox A9 
 
I 
Id2, inhibitor of DNA binding 2 
IFN, interferon 
IFNα-R, interferon-alpha receptor 
IFN γ -R, interferon-gamma receptor 
Ig, immunoglobulin 
IL-7Rα, Interleukin 7 receptor alpha 
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IPA, ingenuity pathway analysis 
 
 
 
L 
LMPP, lymphoid primed multipotent progenitor  
Ly-6D, lymphocyte antigen 6 complex, locus D 
 
M 
MHC, major histocompatibility complex 
 
N 
NK, natural killer 
 
P 
PAX5, paired box gene 5 
PBS, phosphate buffered saline  
pDC, plasmacytoid dendritic cell 
Pu-1, spleen focus forming virus pro-viral integration oncogene 
 
Q  
qRTPCR, quantitative real-time polymerase chain reaction 
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R  
RAG, recombination activating gene 
RNA, ribonucleic acid 
 
S 
Sca-1, lymphocyte antigen 6 complex, locus A/E 
SCF, stem cell factor 
 
T 
TCF1, T cell factor-1 
TCR, T cell receptor 
TLR, toll-like receptor 
TNF, tumor necrosis factor 
 
W 
WT, wild type 
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